Hypertension News

LONG BEACH, Calif. — Progression toward chronic kidney disease was similar in a Veterans Affairs Health Care System study of patients on either chlorthalidone or hydrochlorothiazide, according to a study presented here.

Using an electronic health record algorithm and practice facilitators in primary care did not reduce hospitalizations in adults with chronic kidney disease, type 2 diabetes and hypertension, according to results of a study.

An expert panel released the first consensus statement on performance measures to identify remission and evaluate the effectiveness of lifestyle treatment medications.

Idorsia announced that the FDA has approved aprocitentan, its antihypertensive drug, for treatment of hypertension in combination with other drugs in patients whose BP is not adequately controlled on other drugs.

An op-ed published in February by Tom Frieden, MD, MPH, former director of the CDC, described hypertension as “the deadliest but most neglected and widespread pandemic of our time” — and he’s right.

A computerized clinical decision support system could improve the management of uncontrolled hypertension in adults with chronic kidney disease, according to published data.

Alnylam announced that the KARDIA-2 phase 2 trial of its novel injectable antihypertensive drug zilebesiran met its primary endpoint.

Several indicators of structural racism were linked with a higher prevalence of chronic health conditions in residential neighborhoods, according to a recently published study.

In November, the FDA approved two renal denervation devices for people with uncontrolled hypertension despite maximally tolerated therapies. The approvals ushered in the first-ever interventional procedures with indications to lower BP.

Healio has compiled a list of its most-read hypertension care news in 2023.